Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 44 | 2023 | 712 | 3.910 |
Why?
|
| Anti-HIV Agents | 23 | 2023 | 159 | 2.730 |
Why?
|
| HIV-1 | 14 | 2015 | 71 | 1.750 |
Why?
|
| Pyridazines | 5 | 2010 | 6 | 0.910 |
Why?
|
| CD4 Lymphocyte Count | 20 | 2022 | 181 | 0.870 |
Why?
|
| Viral Load | 16 | 2018 | 135 | 0.860 |
Why?
|
| Antiviral Agents | 7 | 2020 | 100 | 0.840 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2013 | 25 | 0.800 |
Why?
|
| Adult | 49 | 2023 | 7529 | 0.780 |
Why?
|
| Antiretroviral Therapy, Highly Active | 11 | 2017 | 91 | 0.720 |
Why?
|
| Hepatitis C, Chronic | 7 | 2015 | 75 | 0.700 |
Why?
|
| Male | 49 | 2023 | 9843 | 0.660 |
Why?
|
| Humans | 62 | 2023 | 17376 | 0.640 |
Why?
|
| Middle Aged | 40 | 2023 | 7885 | 0.610 |
Why?
|
| Female | 48 | 2023 | 12444 | 0.590 |
Why?
|
| Electronics, Medical | 1 | 2018 | 3 | 0.580 |
Why?
|
| Hepacivirus | 7 | 2015 | 52 | 0.560 |
Why?
|
| Carbamates | 6 | 2015 | 8 | 0.550 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2017 | 63 | 0.530 |
Why?
|
| Sofosbuvir | 5 | 2015 | 5 | 0.530 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 4 | 2015 | 4 | 0.500 |
Why?
|
| Cohort Studies | 21 | 2023 | 2526 | 0.490 |
Why?
|
| Treatment Outcome | 19 | 2020 | 1170 | 0.480 |
Why?
|
| Hepatitis B | 3 | 2022 | 45 | 0.460 |
Why?
|
| California | 19 | 2018 | 2317 | 0.440 |
Why?
|
| Pyrrolidinones | 3 | 2014 | 4 | 0.430 |
Why?
|
| Hepatitis B Vaccines | 4 | 2023 | 44 | 0.430 |
Why?
|
| Electronic Health Records | 1 | 2018 | 707 | 0.390 |
Why?
|
| Liver Diseases | 1 | 2012 | 24 | 0.390 |
Why?
|
| Anti-Retroviral Agents | 6 | 2015 | 82 | 0.390 |
Why?
|
| Young Adult | 15 | 2018 | 2473 | 0.370 |
Why?
|
| HIV Envelope Protein gp41 | 3 | 2010 | 4 | 0.360 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 225 | 0.360 |
Why?
|
| Peptide Fragments | 3 | 2010 | 28 | 0.360 |
Why?
|
| Raltegravir Potassium | 4 | 2018 | 9 | 0.340 |
Why?
|
| Drug Resistance, Viral | 7 | 2015 | 12 | 0.330 |
Why?
|
| Aged | 21 | 2020 | 6129 | 0.310 |
Why?
|
| Life Expectancy | 2 | 2020 | 34 | 0.290 |
Why?
|
| Neoplasms | 4 | 2015 | 448 | 0.270 |
Why?
|
| Prenatal Care | 1 | 2008 | 127 | 0.270 |
Why?
|
| Exercise Therapy | 2 | 2019 | 72 | 0.270 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 151 | 0.260 |
Why?
|
| RNA, Viral | 8 | 2015 | 65 | 0.260 |
Why?
|
| Hospitalization | 4 | 2023 | 805 | 0.250 |
Why?
|
| Ritonavir | 4 | 2010 | 15 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 196 | 0.240 |
Why?
|
| HIV | 2 | 2017 | 26 | 0.240 |
Why?
|
| Sulfonamides | 4 | 2014 | 15 | 0.240 |
Why?
|
| Dideoxynucleosides | 3 | 2016 | 8 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 381 | 0.220 |
Why?
|
| Vaccination | 3 | 2020 | 685 | 0.220 |
Why?
|
| Risk Factors | 11 | 2016 | 3255 | 0.210 |
Why?
|
| Adolescent | 8 | 2018 | 3533 | 0.210 |
Why?
|
| Anaphylaxis | 1 | 2023 | 16 | 0.210 |
Why?
|
| Thrombosis | 1 | 2023 | 13 | 0.210 |
Why?
|
| Drug Therapy, Combination | 8 | 2015 | 107 | 0.200 |
Why?
|
| Fractures, Bone | 1 | 2023 | 94 | 0.200 |
Why?
|
| Genotype | 7 | 2015 | 223 | 0.200 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2011 | 18 | 0.200 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2023 | 59 | 0.190 |
Why?
|
| Risk | 3 | 2020 | 498 | 0.190 |
Why?
|
| Incidence | 7 | 2016 | 1266 | 0.190 |
Why?
|
| Mutation | 3 | 2012 | 132 | 0.190 |
Why?
|
| Herpes Zoster | 1 | 2023 | 82 | 0.190 |
Why?
|
| Case-Control Studies | 5 | 2020 | 1100 | 0.190 |
Why?
|
| Patient Compliance | 4 | 2014 | 278 | 0.190 |
Why?
|
| HIV Protease Inhibitors | 3 | 2010 | 24 | 0.190 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2012 | 2 | 0.180 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 18 | 0.180 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 12 | 0.170 |
Why?
|
| Oligopeptides | 3 | 2010 | 7 | 0.170 |
Why?
|
| Pyridines | 3 | 2010 | 9 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 4 | 0.170 |
Why?
|
| Alanine | 1 | 2020 | 6 | 0.170 |
Why?
|
| HIV Protease | 2 | 2010 | 4 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 537 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.160 |
Why?
|
| Mentoring | 1 | 2019 | 26 | 0.160 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 144 | 0.150 |
Why?
|
| Walking | 2 | 2019 | 89 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2023 | 2428 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1942 | 0.150 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 96 | 0.140 |
Why?
|
| Tablets | 1 | 2017 | 2 | 0.140 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.140 |
Why?
|
| Psoriasis | 1 | 2017 | 9 | 0.140 |
Why?
|
| Organophosphonates | 3 | 2014 | 7 | 0.130 |
Why?
|
| Adenine | 3 | 2014 | 8 | 0.130 |
Why?
|
| Heart Failure | 1 | 2022 | 404 | 0.130 |
Why?
|
| Pneumonia | 1 | 2017 | 49 | 0.130 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 44 | 0.130 |
Why?
|
| Darunavir | 3 | 2010 | 4 | 0.130 |
Why?
|
| Tenofovir | 4 | 2023 | 18 | 0.130 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 538 | 0.130 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 68 | 0.130 |
Why?
|
| Quality of Life | 2 | 2019 | 505 | 0.130 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 1 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2015 | 6 | 0.120 |
Why?
|
| Fluorenes | 1 | 2015 | 5 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2022 | 1229 | 0.120 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 100 | 0.120 |
Why?
|
| Coinfection | 1 | 2015 | 31 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2014 | 1 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 104 | 0.110 |
Why?
|
| Imidazoles | 1 | 2014 | 4 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2011 | 26 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2015 | 64 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 76 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 274 | 0.110 |
Why?
|
| United States | 5 | 2020 | 3891 | 0.110 |
Why?
|
| Continental Population Groups | 1 | 2015 | 289 | 0.110 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2013 | 3 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 190 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 153 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 270 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 205 | 0.100 |
Why?
|
| Registries | 3 | 2012 | 460 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2021 | 729 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 6 | 0.100 |
Why?
|
| Hepatitis B, Chronic | 1 | 2012 | 33 | 0.100 |
Why?
|
| Viremia | 1 | 2012 | 9 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2012 | 6 | 0.100 |
Why?
|
| Health Maintenance Organizations | 3 | 2008 | 408 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2014 | 309 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 31 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 263 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 280 | 0.090 |
Why?
|
| Stroke | 1 | 2014 | 310 | 0.090 |
Why?
|
| Liver Cirrhosis | 3 | 2015 | 41 | 0.090 |
Why?
|
| Home Care Services | 1 | 2011 | 28 | 0.090 |
Why?
|
| Drug Combinations | 3 | 2015 | 43 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2011 | 68 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 88 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 533 | 0.090 |
Why?
|
| Ethnic Groups | 2 | 2015 | 456 | 0.080 |
Why?
|
| Fanconi Syndrome | 1 | 2010 | 5 | 0.080 |
Why?
|
| Social Support | 3 | 2019 | 208 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2015 | 16 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 134 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 120 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 165 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1155 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 109 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2008 | 9 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 395 | 0.080 |
Why?
|
| Birth Certificates | 1 | 2008 | 24 | 0.070 |
Why?
|
| Alcoholism | 1 | 2012 | 337 | 0.070 |
Why?
|
| Lamivudine | 1 | 2008 | 1 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 316 | 0.070 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 46 | 0.070 |
Why?
|
| Hispanic Americans | 2 | 2015 | 378 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 424 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 152 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2015 | 142 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 259 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2008 | 185 | 0.060 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2015 | 2 | 0.060 |
Why?
|
| Atazanavir Sulfate | 3 | 2010 | 5 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 564 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.050 |
Why?
|
| Pregnancy | 1 | 2008 | 1466 | 0.050 |
Why?
|
| Mexican Americans | 1 | 2003 | 42 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 62 | 0.050 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 44 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 380 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 101 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2023 | 127 | 0.050 |
Why?
|
| Creatinine | 2 | 2014 | 66 | 0.050 |
Why?
|
| Child | 1 | 2008 | 2382 | 0.050 |
Why?
|
| Least-Squares Analysis | 2 | 2012 | 14 | 0.050 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 27 | 0.050 |
Why?
|
| Medication Adherence | 2 | 2015 | 239 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2017 | 1079 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 47 | 0.040 |
Why?
|
| Age Factors | 2 | 2014 | 884 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 11 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2020 | 65 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 72 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 124 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 175 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 285 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 257 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 405 | 0.030 |
Why?
|
| Los Angeles | 2 | 2011 | 139 | 0.030 |
Why?
|
| Serogroup | 1 | 2016 | 10 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 21 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 59 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 104 | 0.030 |
Why?
|
| Ribavirin | 1 | 2015 | 8 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 65 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 67 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 671 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 180 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 165 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 239 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 124 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 116 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 203 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 15 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 83 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cobicistat | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 7 | 0.030 |
Why?
|
| Quinolones | 1 | 2014 | 4 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 10 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 15 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 193 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 25 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2014 | 19 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 23 | 0.030 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 208 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 10 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 26 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 480 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 677 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 160 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 702 | 0.030 |
Why?
|
| SEER Program | 1 | 2012 | 94 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 31 | 0.020 |
Why?
|
| Nucleosides | 1 | 2012 | 1 | 0.020 |
Why?
|
| Zidovudine | 1 | 2012 | 1 | 0.020 |
Why?
|
| Thymidine | 1 | 2012 | 2 | 0.020 |
Why?
|
| Virus Replication | 1 | 2011 | 13 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 607 | 0.020 |
Why?
|
| Genomics | 1 | 2012 | 56 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 2011 | 13 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 148 | 0.020 |
Why?
|
| Insurance Benefits | 1 | 2011 | 13 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 937 | 0.020 |
Why?
|
| African Americans | 1 | 2014 | 443 | 0.020 |
Why?
|
| Pyrones | 1 | 2010 | 1 | 0.020 |
Why?
|
| Saquinavir | 1 | 2010 | 1 | 0.020 |
Why?
|
| Lopinavir | 1 | 2010 | 5 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 5 | 0.020 |
Why?
|
| Indinavir | 1 | 2010 | 6 | 0.020 |
Why?
|
| Nelfinavir | 1 | 2010 | 4 | 0.020 |
Why?
|
| Organophosphates | 1 | 2010 | 11 | 0.020 |
Why?
|
| Exanthema | 1 | 2010 | 7 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 62 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 215 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 26 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 226 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 22 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 609 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 56 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 604 | 0.020 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 211 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1044 | 0.020 |
Why?
|
| Medical Indigency | 1 | 2006 | 4 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2006 | 84 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 644 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 884 | 0.020 |
Why?
|
| AIDS Dementia Complex | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2003 | 3 | 0.010 |
Why?
|
| Mexico | 1 | 2003 | 18 | 0.010 |
Why?
|
| Life Style | 1 | 2003 | 316 | 0.010 |
Why?
|
Concepts
(263)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->